These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 32657894)

  • 1. Recent therapeutic prospects for Machado-Joseph disease.
    Costa MDC
    Curr Opin Neurol; 2020 Aug; 33(4):519-526. PubMed ID: 32657894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Planning Future Clinical Trials for Machado-Joseph Disease.
    Saute JAM; Jardim LB
    Adv Exp Med Biol; 2018; 1049():321-348. PubMed ID: 29427112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics.
    Paulino R; Nóbrega C
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preimplantation Genetic Testing of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease-Robust Tools for Direct and Indirect Detection of the
    Lian M; Tan VJ; Taguchi R; Zhao M; Phang GP; Tan AS; Liu S; Lee CG; Chong SS
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machado Joseph-Disease Is Rare in the Peruvian Population.
    Cornejo-Olivas M; Solis-Ponce L; Araujo-Aliaga I; Milla-Neyra K; Ortega O; Illanes-Manrique M; Mazzetti P; Manrique-Enciso C; Cubas-Montecino D; Saraiva-Pereira ML; Jardim LB; Sarapura-Castro E
    Cerebellum; 2023 Dec; 22(6):1192-1199. PubMed ID: 36323979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machado-Joseph disease/spinocerebellar ataxia type 3.
    Paulson H
    Handb Clin Neurol; 2012; 103():437-49. PubMed ID: 21827905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective forces acting on spinocerebellar ataxia type 3/Machado-Joseph disease recurrency: A systematic review and meta-analysis.
    Sena LS; Dos Santos Pinheiro J; Saraiva-Pereira ML; Jardim LB
    Clin Genet; 2021 Mar; 99(3):347-358. PubMed ID: 33219521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Serum GFAP Levels in SCA3/MJD May Not Correlate with Disease Progression.
    Shi Y; Wang C; Huang F; Chen Z; Sun Z; Wang J; Tang B; Ashizawa T; Klockgether T; Jiang H
    Cerebellum; 2015 Dec; 14(6):677-81. PubMed ID: 25869927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of methylation status in the ATXN3 gene promoter region is linked to the SCA3/MJD.
    Wang C; Peng H; Li J; Ding D; Chen Z; Long Z; Peng Y; Zhou X; Ye W; Li K; Xu Q; Ai S; Song C; Weng L; Qiu R; Xia K; Tang B; Jiang H
    Neurobiol Aging; 2017 May; 53():192.e5-192.e10. PubMed ID: 28094059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
    McLoughlin HS; Moore LR; Chopra R; Komlo R; McKenzie M; Blumenstein KG; Zhao H; Kordasiewicz HB; Shakkottai VG; Paulson HL
    Ann Neurol; 2018 Jul; 84(1):64-77. PubMed ID: 29908063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two novel SNPs in ATXN3 3' UTR may decrease age at onset of SCA3/MJD in Chinese patients.
    Long Z; Chen Z; Wang C; Huang F; Peng H; Hou X; Ding D; Ye W; Wang J; Pan Q; Li J; Xia K; Tang B; Ashizawa T; Jiang H
    PLoS One; 2015; 10(2):e0117488. PubMed ID: 25689313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3.
    Watchon M; Robinson KJ; Luu L; An Y; Yuan KC; Plenderleith SK; Cheng F; Don EK; Nicholson GA; Lee A; Laird AS
    FASEB J; 2024 Jan; 38(2):e23429. PubMed ID: 38258931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of human iPS cell line IBCHi002-A from spinocerebellar ataxia type 3/Machado-Joseph disease patient's fibroblasts.
    Ciolak A; Krzyzosiak WJ; Kozlowska E; Fiszer A
    Stem Cell Res; 2020 May; 45():101796. PubMed ID: 32361312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation.
    Da Silva JD; Teixeira-Castro A; Maciel P
    Neurotherapeutics; 2019 Oct; 16(4):1009-1031. PubMed ID: 31691128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yemenite-Jewish families with Machado-Joseph disease (MJD/SCA3) share a recent common ancestor.
    Sharony R; Martins S; Costa IPD; Zaltzman R; Amorim A; Sequeiros J; Gordon CR
    Eur J Hum Genet; 2019 Nov; 27(11):1731-1737. PubMed ID: 31189928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of an induced pluripotent stem cell line from a patient with spinocerebellar ataxia type 3 (SCA3): HIHCNi002-A.
    Hayer SN; Schelling Y; Huebener-Schmid J; Weber JJ; Hauser S; Schöls L
    Stem Cell Res; 2018 Jul; 30():171-174. PubMed ID: 29936336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOE ε2 allele may decrease the age at onset in patients with spinocerebellar ataxia type 3 or Machado-Joseph disease from the Chinese Han population.
    Peng H; Wang C; Chen Z; Sun Z; Jiao B; Li K; Huang F; Hou X; Wang J; Shen L; Xia K; Tang B; Jiang H
    Neurobiol Aging; 2014 Sep; 35(9):2179.e15-8. PubMed ID: 24746364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds.
    Tang B; Liu C; Shen L; Dai H; Pan Q; Jing L; Ouyang S; Xia J
    Arch Neurol; 2000 Apr; 57(4):540-4. PubMed ID: 10768629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
    Li X; Liu H; Fischhaber PL; Tang TS
    Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular vesicle-based delivery of silencing sequences for the treatment of Machado-Joseph disease/spinocerebellar ataxia type 3.
    Rufino-Ramos D; Albuquerque PR; Leandro K; Carmona V; Martins IM; Fernandes R; Henriques C; Lobo D; Faro R; Perfeito R; Mendonça LS; Pereira D; Gomes CM; Nobre RJ; Pereira de Almeida L
    Mol Ther; 2023 May; 31(5):1275-1292. PubMed ID: 37025062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.